Skip to main content

Advertisement

Table 2 Meta-analyses on preoperative treatment (RT; RTCT; CT) versus surgery

From: Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach

  Primary tumor site Range of recruitment periods N° trial N° trial N° total pts N° pts RT±CT arms N° pts CT arms N° pts surgery arms Dose range (Gy) Hystology Hazard ratio SVV benefit SVV benefit
     Including RT        (95% CI ; p) 2 yy 5 yy
Arnott[42] Esophagus 1973-1988 5 5 1147 573 - 574 20-40 SCC-86% 0.89 4% 3%
       (520 RT alone + 53 RTCT)     ADC-14% (CI 0.78-1.01; p=0.06)   
Fiorica[47] Esophagus 1983-1995 6 6 764 385 - 379 20-45 SCC-76% 0.53 NS NS
           ADC-24% (CI 0.31-0.92; p=0.03)   
Sjoquist[39] Esophagus 1982-2008 24 14 4188 1079 1046 2063 20-50.4 SCC-48.9% RTCT: 0.78 RTCT: 8.7% NR
(CI 0.70-0.88; p<0.0001)
ADC-35.5% CT: 0.87 CT: 5.1%
(CI 0.79-0.96; p=0.005)
RTCT vs CT: 0.88
            (CI 0.76-1.01; p=0.07)   
Ronellenfitsch[16] Esophagus + Stomach + GEJ 1987-2004 14 4 2422 198 1024 1200 35-50.4 SCC-0% CT (±RT):0.81 NS CT (±RT):9%
(CI 0.73-0.89; p<0.0001)
ADC-100% RTCT: 0.70
(CI 0.50-0.99; p=0.38)
CT: 0.83
            (CI 0.75-0.91; p=0.38)   
  1. [Pts: patients; Gy: Gray; pCR: pathological complete response; RT: Radiotherapy; CT: Chemotherapy; RTCT: radiochemotherapy; yy: years ; CI: Confidence Interval; SVV: survival; SCC: Squamous Cellular Carcinoma; ADC: Adenocarcinoma; GEJ: Gastroesophageal Junction; NS: Not Specified; NR: Not Reported].